Edition:
Deutschland

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

90.22EUR
14:20 Uhr
Change (% chg)

€0.16 (+0.18%)
Prev Close
€90.06
Open
€89.90
Day's High
€90.42
Day's Low
€89.12
Volume
152,616
Avg. Vol
572,172
52-wk High
€100.20
52-wk Low
€74.54

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and... (more)

Buy/Sell

Sell Hold Buy
2.48 Mean rating from 27 analysts

Overall

Beta: 1.01
Market Cap(Mil.): €12,352.97
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.26

UPDATE 1-European nations weigh impact of Brexit on drug supplies

FRANKFURT/DUBLIN, Jan 15 Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs, while Ireland has drawn up a list of 24 medicines whose supply would be most vulnerable if Britain fails to conclude a divorce deal.

European nations weigh impact of Brexit on drug supplies

FRANKFURT/DUBLIN, Jan 15 Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs while Ireland has drawn up a watch list of some 24 medicines whose supply would be most vulnerable if Britain crashes out without a divorce deal.

German stocks - Factors to watch on Dec. 27

BERLIN, Dec 27 The following are some of the factors that may move German stocks on Thursday:

UPDATE 2-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug, Bavencio, to treat a form of ovarian cancer in previously untreated patients.

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

German stocks - Factors to watch on Dec. 14

BERLIN, Dec 14 The following are some of the factors that may move German stocks on Friday:

Photo

Big pharma leaves big gaps: drugmakers urged to do more for poor

LONDON Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday.

Big pharma leaves big gaps: drugmakers urged to do more for poor

LONDON, Nov 20 Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.46%
Rohstoffe -0.16%
Industrie -0.07%
Konjunktur abhängige Waren & Dienstleistungen +0.04%
Konjunktur unabhängige Waren & Dienstleistungen -0.19%
Finanzindustrie -0.06%
Pharma -0.08%
Technologie -0.08%
Telekommunikation -0.01%